Question
What is the efficacy and safety of naproxen, ibuprofen, mefenamic acid, and aspirin for primary dysmenorrhoea (painful periods)?

Data sources
Studies from 1966 to March 1997 were identified by searching Medline, Embase/Excerpta Medica, and Science Citation Index using search terms including dysmenorrhoea, naproxen, ibuprofen, mefenamic acid, aspirin (acetylsalicylic acid), and paracetamol (acetaminophen); reviewing bibliographies of relevant articles; and communicating with manufacturers.

Study selection
Published English language studies were selected if they were randomised controlled trials of naproxen, ibuprofen, mefenamic acid, aspirin, or paracetamol for dysmenorrhoea treatment.

Data extraction
Data were extracted on study design, type of dysmenorrhoea, treatment type and dosage regimen, patient characteristics, pain relief, need for rescue analgesics, restrictions in daily life, absenteeism from work or school, and side effects.

Main results
56 studies met the inclusion criteria. Naproxen and ibuprofen increased pain relief and decreased use of rescue analgesics and restrictions in daily life compared with placebo (table); naproxen also reduced work or school absences. Aspirin increased pain relief, but did not affect use of rescue analgesics or daily life restrictions; mefenamic acid increased pain relief (table). Naproxen was the only drug that had more side effects than placebo.

Conclusions
Naproxen, ibuprofen, mefenamic acid, and aspirin provide at least moderate pain relief for primary dysmenorrhoea. Naproxen and ibuprofen reduce the need for rescue analgesics and reduce restrictions in daily living. Naproxen reduces work or school absences.

<table>
<thead>
<tr>
<th>Study Factor</th>
<th>Weighted Event Rates</th>
<th>RRI (95% CI)</th>
<th>NNT (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome: pain relief</td>
<td>Naproxen (10) 13% 51% 62% (39 to 108) 4 (3 to 5)</td>
<td>21% (95% CI) Not significant</td>
<td></td>
</tr>
<tr>
<td>Outcome: pain relief</td>
<td>Ibuprofen (9) 14% 55% 74% (58 to 84) 3 (2 to 5)</td>
<td>30% (95% CI) Not significant</td>
<td></td>
</tr>
<tr>
<td>Outcome: pain relief</td>
<td>Aspirin (5) 15% 62% 18% (95% CI) Not significant</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Various analgesics v placebo for dysmenorrhoea

Data were extracted on study design, type of dysmenorrhoea, treatment type and dosage regimen, patient characteristics, pain relief, need for rescue analgesics, restrictions in daily life, absenteeism from work or school, and side effects.

Main results
56 studies met the inclusion criteria. Naproxen and ibuprofen increased pain relief and decreased use of rescue analgesics and restrictions in daily life compared with placebo (table); naproxen also reduced work or school absences. Aspirin increased pain relief, but did not affect use of rescue analgesics or daily life restrictions; mefenamic acid increased pain relief (table). Naproxen was the only drug that had more side effects than placebo (p ≤ 0.05). Direct comparisons of drugs showed that naproxen was better for pain relief than mefenamic acid or aspirin; ibuprofen was better than aspirin.

Commentary
Dysmenorrhoea affects 50% of menstruating women. This meta-analysis by Zhang and Li Wan Po provides a safety and efficacy profile of commonly used analgesics in the treatment of primary dysmenorrhoea. Ibuprofen, which is increasingly available in over the counter formulations, had the most favourable efficacy to side effect profile. As shown in the table, 70% of women taking ibuprofen had pain relief compared with 51% taking placebo (a relative benefit increase of 41%). This means that 3 women with dysmenorrhoea would need to be treated with ibuprofen to achieve pain relief in 1 additional woman. Similarly, ibuprofen reduced the need for rescue analgesics by 79%. Weaknesses of this meta-analysis are the exclusion of unpublished research and studies published in languages other than English.

5–20% of women experience dysmenorrhoea of incapacitating severity. Research indicates that < 33% of women with dysmenorrhoea seek treatment from a physician. Therefore, nurses in community based settings have a unique opportunity to educate women on the findings of this study, particularly the effectiveness of ibuprofen for pain relief with minimal side effects. This study is relevant to occupational health nurses because of their focus on increasing work performance and attendance and to health nurses in schools, where dysmenorrhoea may affect school attendance. For women’s health practitioners, the results emphasise the effectiveness of a familiar and relatively inexpensive non-steroidal anti-inflammatory drug in the first line management of primary dysmenorrhoea.

Tammy Anderer, CRNP, MSN
Family Nurse Practitioner and Nursing Faculty
The Penn State Geisinger Health System and Lycoming College
Williamsport, Pennsylvania, USA